Palisade Bio (PALI) Free Cash Flow (2010 - 2026)
Palisade Bio (PALI) posted quarterly Free Cash Flow of -$3.9 million for Q1 2026, down 66.74% year-over-year from -$11.7 million in Q1 2025, and down 23.73% quarter-over-quarter from -$3.1 million in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Free Cash Flow (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Free Cash Flow for 17 consecutive years, with -$3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 66.74% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$12.4 million (down 9.32% YoY), while the FY2025 annual figure was -$10.8 million, up 11.04% from the prior year.
- Free Cash Flow declined to -$3.9 million in Q1 2026 per PALI's latest filing, from -$3.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.8 million in Q2 2025 and bottomed at -$3.9 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$3.0 million across 5 years, with a median of -$3.1 million in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 57.91% in 2022 and fell as far as 201.12% in 2022.
- Palisade Bio's Free Cash Flow stood at -$3.3 million in 2022, then gained by 17.19% to -$2.7 million in 2023, then increased by 13.29% to -$2.4 million in 2024, then tumbled by 32.05% to -$3.1 million in 2025, then dropped by 23.73% to -$3.9 million in 2026.
- Business Quant data shows PALI's Free Cash Flow at -$3.9 million in Q1 2026, -$3.1 million in Q4 2025, and -$3.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | -7.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Mn |
| Mar 31, 2026 | -3.89 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.55 Mn |
| Jun 30, 2025 | -1.82 Mn |
| Mar 31, 2025 | -2.33 Mn |
| Dec 31, 2024 | -2.38 Mn |
| Sep 30, 2024 | -3.13 Mn |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | -3.18 Mn |
| Dec 31, 2023 | -2.75 Mn |
| Sep 30, 2023 | -2.66 Mn |
| Jun 30, 2023 | -2.20 Mn |
| Mar 31, 2023 | -3.53 Mn |
| Dec 31, 2022 | -3.32 Mn |
| Sep 30, 2022 | -3.04 Mn |
| Jun 30, 2022 | -3.25 Mn |
| Mar 31, 2022 | -3.76 Mn |
| Dec 31, 2021 | -3.06 Mn |
| Sep 30, 2021 | -2.75 Mn |